Zloza A - Search Results

1

Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study.

Kaufman HL, Amatruda T, Reid T, Gonzalez R, Glaspy J, Whitman E, Harrington K, Nemunaitis J, Zloza A, Wolf M, Senzer NN. Kaufman HL, et al. Among authors: zloza a. J Immunother Cancer. 2016 Mar 15;4:12. doi: 10.1186/s40425-016-0116-2. eCollection 2016. J Immunother Cancer. 2016. PMID: 26981242 Free PMC article.

2

Results of a randomized phase I gene therapy clinical trial of nononcolytic fowlpox viruses encoding T cell costimulatory molecules.

Kaufman HL, Kim DW, Kim-Schulze S, DeRaffele G, Jagoda MC, Broucek JR, Zloza A. Kaufman HL, et al. Among authors: zloza a. Hum Gene Ther. 2014 May;25(5):452-60. doi: 10.1089/hum.2013.217. Epub 2014 Mar 26. Hum Gene Ther. 2014. PMID: 24484178 Free PMC article. Clinical Trial.

3

Immunoglobulin-like transcript 2 (ILT2) is a biomarker of therapeutic response to oncolytic immunotherapy with vaccinia viruses.

Zloza A, Kim DW, Kim-Schulze S, Jagoda MC, Monsurro V, Marincola FM, Kaufman HL. Zloza A, et al. J Immunother Cancer. 2014 Jan 27;2:1. doi: 10.1186/2051-1426-2-1. eCollection 2014. J Immunother Cancer. 2014. PMID: 24829758 Free PMC article.

4

Interleukin-2 alters distribution of CD144 (VE-cadherin) in endothelial cells.

Kim DW, Zloza A, Broucek J, Schenkel JM, Ruby C, Samaha G, Kaufman HL. Kim DW, et al. Among authors: zloza a. J Transl Med. 2014 May 6;12:113. doi: 10.1186/1479-5876-12-113. J Transl Med. 2014. PMID: 24885155 Free PMC article.

5

High-dose IL-2 induces rapid albumin uptake by endothelial cells through Src-dependent caveolae-mediated endocytosis.

Zloza A, Kim DW, Broucek J, Schenkel JM, Kaufman HL. Zloza A, et al. J Interferon Cytokine Res. 2014 Nov;34(11):915-9. doi: 10.1089/jir.2013.0155. Epub 2014 Jun 25. J Interferon Cytokine Res. 2014. PMID: 24963699 Free PMC article.

6

NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade.

Kohlhapp FJ, Broucek JR, Hughes T, Huelsmann EJ, Lusciks J, Zayas JP, Dolubizno H, Fleetwood VA, Grin A, Hill GE, Poshepny JL, Nabatiyan A, Ruby CE, Snook JD, Rudra JS, Schenkel JM, Masopust D, Zloza A, Kaufman HL. Kohlhapp FJ, et al. Among authors: zloza a. J Immunother Cancer. 2015 May 19;3:18. doi: 10.1186/s40425-015-0063-3. eCollection 2015. J Immunother Cancer. 2015. PMID: 25992289 Free PMC article.

7

Oncolytic viruses: a new class of immunotherapy drugs.

Kaufman HL, Kohlhapp FJ, Zloza A. Kaufman HL, et al. Among authors: zloza a. Nat Rev Drug Discov. 2015 Sep;14(9):642-62. doi: 10.1038/nrd4663. Nat Rev Drug Discov. 2015. PMID: 26323545 Free PMC article. Review.

8

Talimogene laherparepvec (T-VEC) as cancer immunotherapy.

Kohlhapp FJ, Zloza A, Kaufman HL. Kohlhapp FJ, et al. Among authors: zloza a. Drugs Today (Barc). 2015 Sep;51(9):549-58. doi: 10.1358/dot.2015.51.9.2383044. Drugs Today (Barc). 2015. PMID: 26488034 Review.

9

IFN-λ cancer immunotherapy: new kid on the block.

Lasfar A, Gogas H, Zloza A, Kaufman HL, Kirkwood JM. Lasfar A, et al. Among authors: zloza a. Immunotherapy. 2016 Jul;8(8):877-88. doi: 10.2217/imt-2015-0021. Immunotherapy. 2016. PMID: 27381684 Free PMC article. Review.

10

Low-dose interleukin-2 impairs host anti-tumor immunity and inhibits therapeutic responses in a mouse model of melanoma.

Zloza A, Dharmadhikari ND, Huelsmann EJ, Broucek JR, Hughes T, Kohlhapp FJ, Kaufman HL. Zloza A, et al. Cancer Immunol Immunother. 2017 Jan;66(1):9-16. doi: 10.1007/s00262-016-1916-4. Epub 2016 Oct 18. Cancer Immunol Immunother. 2017. PMID: 27757560 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

73 results

Search Page